Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed transplant-ineligible multiple myeloma patients.

Trial Details

NCT ID
NCT05272826
Phase
PHASE2
Sponsor
Canadian Myeloma Research Group
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Iberdomide
  • Bortezomib
  • Dexamethasone
  • Isatuximab
Locations (sample)
  • Edmonton, Alberta, Canada|53.55014,-113.46871
  • St. John's, Newfoundland and Labrador, Canada|47.56494,-52.70931
  • Halifax, Nova Scotia, Canada|44.64269,-63.57688
  • London, Ontario, Canada|42.98339,-81.23304
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Must understand and voluntarily sign informed consent form
  • Age ≥ 65 years at the time of signing consent
  • Must be able to adhere to the study visit schedule and other protocol requirements.
  • Previously untreated, transplant ineligible, symptomatic multiple myeloma as defined by the criteria below.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →